Previous Close | 2.7700 |
Open | 2.8800 |
Bid | 3.1100 x 400 |
Ask | 3.1400 x 200 |
Day's Range | 2.8390 - 3.1500 |
52 Week Range | 2.2150 - 12.3600 |
Volume | |
Avg. Volume | 793,940 |
Market Cap | 702.078M |
Beta (5Y Monthly) | 2.51 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Organizational redesign and rightsizing initiated across company to streamline structures, increase efficiency and reduce operating costs Together with GSK, ended Pandemic Preparedness Agreement (PPA) with Federal Republic of Germany, after consultation ...
Mr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-making Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic ...
Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat Study will assess monovalent vaccine candidate, encoding ...